Actively Recruiting
Safety and Pharmacokinetics of Oral Clemastine in Premature Infants With White Matter Injury
Led by Bridget LaMonica Ostrem, M.D., Ph.D. · Updated on 2026-07-28
24
Participants Needed
1
Research Sites
169 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating clemastine, an experimental drug, for treating white matter injury, a common brain injury in premature infants. This Phase IIb study focuses on assessing the safety and how the drug moves through and stays in the bodies of infants with this condition. White matter injury in preterm infants is linked to motor and cognitive disabilities and seizures, with no current therapies to promote brain repair or myelination at the time injury is identified. Participants will receive oral clemastine in escalating doses starting at 0.01 mgkgday up to 0.05 mgkgday during the study. This open-label trial includes a dose-escalation and dose-expansion design to test safety and pharmacokinetics. Treatment is given while the infants remain hospitalized in intensive care nurseries. The study will monitor for dose-limiting toxicities and adverse events throughout and shortly after drug administration. During the study, infants will undergo imaging to confirm white matter injury and be closely monitored with laboratory tests and clinical evaluations. Researchers will track how much clemastine is absorbed and how long it remains in the infants bodies over the first 15 days of dosing. The primary outcome is the number of infants experiencing dose-limiting toxicities up to 30 days after the last dose. Overall participation lasts through treatment and safety follow-up periods.
CONDITIONS
Brief Title
Neonatal White Matter Injury Trial (WRAP)
Research Team
A
Audrey Hernando, BS
L
Lena Odell, BA
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here